Pharmacologic targets for atrial fibrillation

Research output: Contribution to journalReview article

1 Scopus citations


Despite advances in treatment, atrial fibrillation (AF) remains the most common arrhythmia in humans. Antiarrhythmic drug therapy continues to be a cornerstone of AF treatment, even in light of emerging non-pharmacologic therapies. Conventional antiarrhythmic drugs target cardiac ion channels and are often associated with modest AF suppression and the risk of ventricular proarrhythmia. Ongoing drug development has focused on targeting atrial-specific ion channels as well as novel non-ionic targets. Targeting non-ionic mechanisms may also provide new drugs directed towards the underlying mechanisms responsible for AF and possibly greater antiarrhythmic potency. Agents that act against these new targets may offer improved safety and efficacy in AF treatment.

Original languageEnglish (US)
Pages (from-to)1161-1178
Number of pages18
JournalExpert Opinion on Therapeutic Targets
Issue number9
StatePublished - Sep 1 2007


  • Antiarrhythmic agent
  • Atrial fibrillation
  • Drug therapy
  • Mechanism
  • Pharmacotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Pharmacologic targets for atrial fibrillation'. Together they form a unique fingerprint.

  • Cite this